HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AEOL 11207

a neuroprotective agent; structure in first source

Also Known As:

AEOL-11207; AEOL11207

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Day, Brian J: 2 articles (03/2012 - 04/2007)
2.	Liang, Li-Ping: 2 articles (03/2012 - 04/2007)
3.	Patel, Manisha: 2 articles (03/2012 - 04/2007)
4.	Huang, Ting-Ting: 1 article (03/2012)
5.	Rowley, Shane: 1 article (03/2012)
6.	Waldbaum, Simon: 1 article (03/2012)
7.	Fulton, Ruth: 1 article (04/2007)
8.	Huang, Jie: 1 article (04/2007)

Related Diseases

1.	Parkinsonian Disorders (Parkinsonism) 04/18/2007 - "In this study, we tested the therapeutic effects of a compound [5,15-bis(methoxycarbonyl)-10,20-bis-trifluoromethyl-porphyrinato manganese (III) chloride (AEOL11207)] belonging to a new generation of lipophilic manganic porphyrins for neuroprotection and oral bioavailability in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of parkinsonism. "
2.	Epilepsy (Aura) 03/01/2012 - "To confirm the role of mitochondrial oxidative stress in epilepsy a newly developed lipophilic metalloporphyrin, AEOL 11207, with high potency for catalytic removal of endogenously generated reactive oxygen species was utilized. "

Related Drugs and Biologics

1.	Therapeutic Uses
2.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
3.	Porphyrins
4.	Manganese
5.	Chlorides
6.	Reactive Oxygen Species (Oxygen Radicals)
7.	Metalloporphyrins